This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kovacic, M. B. Articles by Burk, R. D. Search for Related Content PubMed PubMed Citation Articles by Kovacic, M. B. Articles by Burk, R. D.

Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality

¹ Division of Cancer Epidemiology and Genetics and ² Cancer Prevention Fellowship Program, National Cancer Institute, NIH, Bethesda, Maryland; ³ Proyecto Epidemiológico Guanacaste; ⁴ Laboratorio Nacional de Citología, Caja Costarricense de Seguro Social, San Jose, Costa Rica; ⁵ Women and Infants' Hospital, Providence, Rhode Island; and ⁶ Albert Einstein College of Medicine, Bronx, New York

Requests for reprints: Melinda Butsch Kovacic, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Suite 550, EPS MSC 7234, Bethesda, MD 20892-7234. Phone: 301-496-1692; Fax: 301-402-0916; E-mail: kovacicm{at}mail.nih.gov.

Persistent cervical infections with carcinogenic human papillomaviruses (HPV) cause virtually all cervical cancer. Cytologic abnormalities are the manifestations of HPV infections used to identify women at risk. To compare the potential of the full range of anogenital HPV genotypes to induce cytopathic effects, we examined the influences of HPV type, viral load, and age on cytopathology among 1,222 women having a single HPV type at enrollment into a 10,000-woman population-based study in Costa Rica. Cervical specimens were tested for 40 HPV types by MY09/MY11 L1 primer PCR and type-specific dot blot hybridization. Types were organized by phylogenetic species and cancer risk. PCR signal strength served as a qualitative surrogate for viral load. Overall, 24.8% [95% confidence interval (95% CI), 22.4-27.3] of single prevalent HPV infections had concurrent abnormalities (atypical squamous cells or worse) ranging from 0.0% to 80.0% based on HPV type. Noncarcinogenic 3/15 types, although highly prevalent, uncommonly caused cytologic abnormalities (13.1%; 95% CI, 9.8-17.0). In contrast, one quarter to nearly one half of infections with a single major carcinogenic species type (9/11/7/5/6) produced abnormalities. Greater abnormalities were observed with increasing qualitative viral load of carcinogenic types; fewer abnormalities were observed among older women (>54 years). A high percentage (46.2%) of detected abnormalities in women infected with HPV16 or related 9 types were high grade or worse, consistent with strong carcinogenicity, compared with 10.7% in women infected with 7 types, including HPV18, a major cause of adenocarcinoma. The lack of evident severe abnormalities associated with HPV18 and related HPV types might have implications for screening for poorly detected glandular and 7-related lesions. (Cancer Res 2006; 66(20): 10112-9)

This article has been cited by other articles:

				B. Dal Bello, A. Spinillo, P. Alberizzi, S. Cesari, B. Gardella, and E. M. Silini Validation of the SPF10 LiPA Human Papillomavirus Typing Assay Using Formalin-Fixed Paraffin-Embedded Cervical Biopsy Samples J. Clin. Microbiol., July 1, 2009; 47(7): 2175 - 2180. [Abstract] [Full Text] [PDF]

				N. Wentzensen, P. E. Gravitt, D. Solomon, C. M. Wheeler, and P. E. Castle A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1341 - 1349. [Abstract] [Full Text] [PDF]

				S. I. Collins, C. Constandinou-Williams, K. Wen, L. S. Young, S. Roberts, P. G. Murray, and C. B.J. Woodman Disruption of the E2 Gene Is a Common and Early Event in the Natural History of Cervical Human Papillomavirus Infection: A Longitudinal Cohort Study Cancer Res., May 1, 2009; 69(9): 3828 - 3832. [Abstract] [Full Text] [PDF]

				M. Safaeian, M. Schiffman, J. Gage, D. Solomon, C. M. Wheeler, and P. E. Castle Detection of Precancerous Cervical Lesions Is Differential by Human Papillomavirus Type Cancer Res., April 15, 2009; 69(8): 3262 - 3266. [Abstract] [Full Text] [PDF]

				C. M. Wheeler, W. C. Hunt, N. E. Joste, C. R. Key, W. G. V. Quint, and P. E. Castle Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States J Natl Cancer Inst, April 1, 2009; 101(7): 475 - 487. [Abstract] [Full Text] [PDF]

				C. Porras, A. C. Rodriguez, A. Hildesheim, R. Herrero, P. Gonzalez, S. Wacholder, R. D. Burk, and M. Schiffman Human Papillomavirus Types by Age in Cervical Cancer Precursors: Predominance of Human Papillomavirus 16 in Young Women Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 863 - 865. [Abstract] [Full Text] [PDF]

				L. F. Xi, L. A. Koutsky, P. E. Castle, C. M. Wheeler, D. A. Galloway, C. Mao, J. Ho, and N. B. Kiviat Human Papillomavirus Type 18 DNA Load and 2-Year Cumulative Diagnoses of Cervical Intraepithelial Neoplasia Grades 2-3 J Natl Cancer Inst, February 4, 2009; 101(3): 153 - 161. [Abstract] [Full Text] [PDF]

				M. Saunier, S. Monnier-Benoit, F. Mauny, V. Dalstein, J. Briolat, D. Riethmuller, B. Kantelip, E. Schwarz, C. Mougin, and J.-L. Pretet Analysis of Human Papillomavirus Type 16 (HPV16) DNA Load and Physical State for Identification of HPV16-Infected Women with High-Grade Lesions or Cervical Carcinoma J. Clin. Microbiol., November 1, 2008; 46(11): 3678 - 3685. [Abstract] [Full Text] [PDF]

				J. Jeronimo, N. Wentzensen, R. Long, M. Schiffman, S. T. Dunn, R. A. Allen, J. L. Walker, M. A. Gold, R. E. Zuna, M. E. Sherman, et al. Evaluation of Linear Array Human Papillomavirus Genotyping Using Automatic Optical Imaging Software J. Clin. Microbiol., August 1, 2008; 46(8): 2759 - 2765. [Abstract] [Full Text] [PDF]

				P. E. Castle Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening? Am. J. Epidemiol., July 15, 2008; 168(2): 138 - 144. [Abstract] [Full Text] [PDF]

				L. Bogaert, M. Van Poucke, C. De Baere, J. Dewulf, L. Peelman, R. Ducatelle, F. Gasthuys, and A. Martens Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid J. Gen. Virol., August 1, 2007; 88(8): 2155 - 2161. [Abstract] [Full Text] [PDF]

				M. Safaeian, R. Herrero, A. Hildesheim, W. Quint, E. Freer, L.-J. Van Doorn, C. Porras, S. Silva, P. Gonzalez, M. C. Bratti, et al. Comparison of the SPF10-LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica J. Clin. Microbiol., May 1, 2007; 45(5): 1447 - 1454. [Abstract] [Full Text] [PDF]

				A. R. Kreimer, H. A. Katki, M. Schiffman, C. M. Wheeler, P. E. Castle, and for the ASCUS-LSIL Triage Study Group Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3 Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 11 - 16. [Abstract] [Full Text] [PDF]